Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

Abstract We report on the randomized portion of the phase 2, open-label CheckMate 650 trial (NCT02985957), in which docetaxel-experienced, biologically male patients with chemotherapy-refractory metastatic castration-resistant prostate cancer were randomized 2:2:1:2 to nivolumab 3 mg /kg plus ipilim...

Descripció completa

Dades bibliogràfiques

Autors principals:	Padmanee Sharma, Michael Krainer, Fred Saad, Daniel Castellano, Jens Bedke, Mariusz Kwiatkowski, Akash Patnaik, Giuseppe Procopio, Paweł Wiechno, Samith Kochuparambil, Christian Thomas, José Ángel Arranz Arija, Steven L. McCune, Steinbjørn Hansen, Gedske Daugaard, Juan Ignacio Delgado Mingorance, Craig Kukard, Sumit K. Subudhi, Sreyashi Basu, Sonali Jindal, Bilal A. Siddiqui, Ana Lako, Saurabh Gupta, Viktor Fedorov, Neha P. Amin, Arancha Campos, Yumeng Wang, Justin M. David, Russell K. Pachynski
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-05-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-026-72242-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!